English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

ferent doses of MMX mesalazine (2.4 and 4.8 g once daily), pH-release mesalazine 2.4 g/day (800 mg thrice daily), and placebo. After 8 weeks, the CR and ER rates were higher in patients who received either MMX mesalazine 2.4 g/day (40.5%, P=0.01) or 4.8 g/day (41.2%, P=0.007). However, pHrelease mesalazine 2.4 g/day was not significantly (32.6%, P=0.124) better than the placebo (22.1%) in terms of CR and ER rates. Generally, MMX mesalazine was well tolerated among the patients in these studies. A subsequent analysis of pooled data from 2 MMX mesalazine phase III studies demonstrated that the administration of 2 doses (2.4 and 4.8 g/day) of mesalazine was effective in inducing CR and ER in patients with mild to moderate UC. In the current issue of Intestinal Research, Ogata et al. investigated the efficacy and safety of 2 doses of MMX mesalazine (2.4 [MMX-2.4 group] and 4.8 g/day [MMX-4.8 group]) compared with controlled-release mesalazine 2.25 g/day (thrice daily, controlled-2.25 group). Patients were randomly assigned either to MMX-2.4 (n=85), MMX-4.8 (n=81), or controlled-2.25 group (n=85) for 8 weeks. The primary endpoint was to demonstrate the non-inferiority of MMX-2.4 g/day to controlled-2.25 g/day and the superiority of MMX-4.8 g/day to controlled-2.25 g/day based on changes in the UC-disease activity index (UC-DAI) score. The secondary endpoints included remission (defined as UC-DAI score ≤2 and rectal bleeding score=0) and ER (defined as UC-DAI subscore=0). Mesalazine (5-aminosalicylic acid, 5-ASA) is the first-line therapy for patients with mild to moderate UC. Mesalazine has been reported to be effective, safe, and well-tolerated in patients with UC. Although the precise mechanism of 5-ASA is not clear, investigations have demonstrated its anti-inflammatory and immunosuppressive properties, which suggests that the mechanism is multifactorial. According to delivery system, mesalazine is divided into different types: (1) pHrelease mesalazine (Asacol), which uses a gastro-resistant coating that dissolves at a pH ≥7; (2) controlled-release mesalazine (Pentasa) consists of microspheres containing mesalazine enclosed within an ethylcellulose semi-permeable membrane, which allows the release of 5-ASA in a timesensitive manner; and (3) multi-matrix system (MMX) mesalazine (Mezavant and Lialda) utilizes a pH-dependent film (pH 7) to resist gastric breakdown and to deliver 5-ASA throughout the colon. The effectiveness of MMX mesalazine in inducing remission has been reported by 2 large phase III studies. In the first study (n=280), clinical remission (CR) and endoscopic remission (ER) rates were higher with both MMX mesalazine 2.4 g/day (1.2 g twice daily; 34.1%, P <0.001) and 4.8 g (once daily; 29.2%, P=0.009) than those with placebo (12.9%)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?